Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Dorine Essey who wrote (300)	8/2/2001 4:22:19 PM
From: Dorine Essey	Respond to of 340

Several drugmakers get OK to sell generic Prozac -------------------------------------------------------------------------------- NEW YORK, Aug 2 (Reuters) - The U.S. Food and Drug Administration said it granted approval for several generic drugmakers to market copycat versions of blockbuster antidepressant Prozac after patent protection over the drug expired for Eli Lilly and Co. . The FDA said Israel's Teva Pharmaceutical Industries Ltd. received approval to market a liquid oral solution of the drug in the dosage of 20 milligrams per 5 milliliters. India's Dr. Reddy's Laboratories was cleared to market a 40 mg. capsule of generic Prozac. Geneva Pharmaceuticals Inc., a unit of Swiss drug giant Novartis , received the go-ahead for U.S. sale of a 10 mg. copycat capsule of Prozac. The FDA cleared Alphapharm, a unit of Germany's Merck KGaA, to market both 10 mg. and 20 mg. generic tablets of the drug. Pharmaceutical Resources Inc. has said it would license the 10 mg. and 20 mg. capsule forms from Alphapharm and the 40 mg. capsule from Dr. Reddy's. The approvals came after Barr Laboratories Inc. said it won approval to market a 20 mg. generic capsule form of Prozac, which accounts for $2.2 billion of Lilly's $2.7 billion in annual sales of the drug. REUTERS Rtr 15:52 08-02-01

To: Dorine Essey who wrote (300)	8/2/2001 8:19:25 PM
From: Dorine Essey	Read Replies (1) \| Respond to of 340

Teva Announces Final Approval of Fluoxetine Oral Solution 180-Day Market Exclusivity JERUSALEM, Israel, Aug 2, 2001 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA chart, msgs) announced today that the U.S. Food and Drug Administration (FDA) has awarded final approval for fluoxetine oral solution. Launch is anticipated to begin immediately. Fluoxetine Oral Solution is the generic version of Dista's antidepressant, Prozac(R) Oral Solution, which had U.S. 2000 branded sales of approximately $30 million. As the first applicant to challenge the listed patents for this drug formulation, Teva is entitled to a 180-day period of generic marketing exclusivity. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 40 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 85% of Teva's sales are outside Israel, mainly in North America and Europe. The company develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. Safe Harbor Statement: This report contains forward-looking statements, which express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward looking statements. Important factors that could cause or contribute to such differences include the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, fluctuations in currency, exchange and interest rates, operating results, and other factors that are discussed in the Company's Annual Report on Form 20-F and the Company's other filings with the U.S. Securities and Exchange Commission. Contact: Teva Pharmaceutical Industries Ltd. Dan Suesskind, (011) 972-2-589-2840 or Investor Relations Dorit Meltzer, (011) 972-3-926-7554 or Teva North America Bill Fletcher, 215/591-8800 www.tevapharm.com